Adjunct Assistant Professor of Biomedical Informatics

Contact Info:

Research Interests

Dr. Lyons-Weiler’s research interests are in (1) optimization of disease prediction modeling in cancer and other diseases, including genetic, genomic and proteomic biomarkers for early detection and therapy response prediction; (2) optimization of survivorship prediction models; (3) decision modeling to optimize the integration of new clinical options into existing clinical workflows and strategies.

Grants

Completed:

• AP Sloan/US DOE Computational Molecular Biology Postdoctoral Fellowship
• NIH National Service Award

Active:

R01 AI60602-01 (Vats)
07/01/04 - 06/30/09
1.20 calendar National Institute of Health $264,382
Biomarker Based studies of Polyomaviruses
Dr. Vats will search for cell-based and serum-based biomarkers that will predict renal transplant rejection.
Role: Co-Investigator

W81XWH-05-2-0005 (Becich)
07/01/05 – 06/30/06
4.32 calendar
DOD $2,641,940
TATRC Western Pennsylvania Proteomics Initiative
Proteomics and Bioinformatics Core Facilities
The objective of the project is to foster new understanding of cancer and other diseases through proteomics – the study of the shape, function and expression of proteins. The primary focus of the project is on new high-throughput technologies that are used to analyze protein expression in patient samples at a high rate of speed and the design of standardized operating procedures maximizing the performance and utility of such technologies. Role: Co-investigator

P30 CA47904 (Herberman) 08/01/2004 – 07/31/2009
2.40 calendar National Institute of Health
$3,370,205 Cancer Center Support Grant
Microarray and Analysis Shared Service (MASS)
Dr. Herberman directs the University of Pittsburgh Cancer Institute.
Role: Co-Investigator

DE016406
National Institute of Health (subaccount to Kahn)
02/01/05-1/31/10
0.6 calendar
$366,294
Genomic and Proteomic Analysis of HPB-Associated SCCHN
This proposal involves the identification of cellular gene expression profiles in fresh tissues from patients with HPV-positive and HPV-negative SCCHN and premalignant lesions. The hypothesis to be tested is that significant changes in gene expression profiles occur during the development of HPB-associated SCCHN, and these profiles are unique to a particular stage of the disease and response to therapy. We will accomplish our goals by using Affymetrix GeneChips representing approximately 22,000 human genes. We will also measure the expression levels of the HPV regulatory E2 gene and the E6 and E7 oncogenes in SCCHN tissues and premalignant lesions.
Role: Co-Investigator

R01 CA90665 (Luketich)
04/01/05-03/31/2010
0.36 calendar National Institute of Health
$252,427
Use of Quantitative RT-PCR for Staging Esophageal Cancer
Dr. Luketich will explore biomarkers for molecular staging of esophageal cancers.
Role: Co-Investigator

Lab Personnel

Graduate Students:

• Holly Perri
• Rick Jordan

Research Staff:

• Haiwen Shi, Programmer II
• Mai Sun, Data Analyst